Probable late lyme disease: A variant manifestation of untreated Borrelia burgdorferi infection

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Aucott, John N ^a   Seifter, Ari ^b   Rebman, Alison W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Lyme Disease Research Foundation of Maryland   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALEXIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DOXYCYCLINE; GLUCOCORTICOID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BURSITIS; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FATIGUE; FEMALE; HUMAN; LYME DISEASE; MALE; MEDICAL RECORD REVIEW; MEMORY DISORDER; MYALGIA; NIGHT SWEAT; PROBABLE LATE LYME DISEASE; RECURRENT DISEASE; VERTIGO;

ADULT; AGED; ANTIBODIES, BACTERIAL; BORRELIA BURGDORFERI; FEMALE; HUMANS; IMMUNOGLOBULIN G; LYME DISEASE; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84864406512     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-173     Document Type: Article

References (20)

1. Alpert B, Esin J, Sivak SL, Wormser GP. Incidence and prevalence of Lyme disease in a suburban Westchester County community. N Y State J Med 1992, 92(1):5-8.
2. Tugwell P, Dennis DT, Weinstein A, Wells G, Shea B, Nichol G, Hayward R, Lightfoot R, Baker P, Steere AC. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997, 127(12):1109-1123.
3. Wormser GP. Clinical practice. Early Lyme disease. N Engl J Med 2006, 354(26):2794-2801.
4. Steere AC, Dhar A, Hernandez J, Fischer PA, Sikand VK, Schoen RT, Nowakowski J, McHugh G, Persing DH. Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease. Am J Med 2003, 114(1):58-62. 10.1016/S0002-9343(02)01440-7, 12543291.
5. Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease-United States, 1992-2006. MMWR Surveill Summ 2008, 57(10):1-9.
6. Centers for Disease Control and Prevention Lyme Disease (Borrelia burgdorferi) 2011 Case Definition 2011, , Borrelia burgdorferi, http://www.cdc.gov/osels/ph_surveillance/nndss/casedef/lyme_disease_current.htm, Centers for Disease Control and Prevention.
7. Reported Lyme disease Cases by State, 1996-2009 , , , [http://www.cdc.gov/lyme/stats/charstables/reportedcases_statelocality.html], Reported Lyme disease Cases by State, 1996-2009.
8. Meek JI, Roberts CL, Smith EV. Cartter ML: Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Manag Pract 1996, 2(4):61-65.
9. Coyle BS, Strickland GT, Liang YY, Pena C, McCarter R, Israel E. The public health impact of Lyme disease in Maryland. J Infect Dis 1996, 173(5):1260-1262. 10.1093/infdis/173.5.1260, 8627082.
10. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43(9):1089-1134. 10.1086/508667, 17029130.
11. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987, 107(5):725-731.
12. Feder HM. Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP, Ad Hoc International Lyme Disease Group, Agger WA, Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, Draper T, McSweegan E, Halperin JJ, Klempner MS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP,Jr, Sood S, Weinstein A, Wong SJ, Zemel L: A critical appraisal of "chronic Lyme disease". N Engl J Med 2007, 357(14):1422-1430. 10.1056/NEJMra072023, 17914043.
13. Anonymous Case definitions for infectious conditions under public health surveillance Centers for Disease Control and Prevention. MMWR Recomm Rep 1997, 46(10):1-55. Anonymous Case definitions for infectious conditions under public health surveillance.
14. Schoen RT A case revealing the natural history of untreated Lyme disease , Nat Rev Rheumatol, , Schoen RT.
15. Aucott J, Morrison C, Munoz B, Rowe PC, Schwarzwalder A, West SK. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis 2009, 9:79. 10.1186/1471-2334-9-79, 2698836, 19486523.
16. Nowakowski J, McKenna D, Nadelman RB, Cooper D, Bittker S, Holmgren D, Pavia C, Johnson RC, Wormser GP. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000, 9(6):563-567. 10.1001/archfami.9.6.563, 10862221.
17. Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006, 54(10):3079-3086. 10.1002/art.22131, 17009226.
18. Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, Jacobs MB, Hasenkampf NR, Martin DS, Narasimhan S, Phillippi-Falkenstein KM, Purcell JE, Ratterree MS, Philipp MT. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 2012, 7(1):e29914. 10.1371/journal.pone.0029914, 3256191, 22253822.
19. Wormser GP, Nadelman RB, Schwartz I. The amber theory of Lyme arthritis: initial description and clinical implications. Clin Rheumatol 2012, : .
20. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 1996, 34(1):1-9. 228718, 8748261.